Description

S4 Andarine + Ligandrol Stack – Product Information

S4 Andarine is a selective androgen receptor modulator (SARM) known for its potential to bind to androgen receptors in muscle and bone tissues. It may promote anabolic effects, potentially leading to increased protein synthesis, muscle growth, and improved muscle strength.

Ligandrol is another selective androgen receptor modulator (SARM) that selectively binds to androgen receptors in muscle and bone tissues. It may promote anabolic effects, potentially leading to increased protein synthesis, muscle growth, and improved muscle strength.

The combination of S4 Andarine and Ligandrol may have a synergistic effect on muscle development. Both compounds target androgen receptors, potentially leading to increased protein synthesis, muscle hypertrophy, and improved strength gains.

Ligandrol’s potential to help preserve muscle mass during caloric deficits, combined with S4 Andarine’s anabolic properties, may provide additional support for muscle preservation and development. This combination may be beneficial for maintaining or increasing muscle mass under various conditions in research subjects.

• S4 Andarine + Ligandrol Stack consists of Andarine S4 and Ligandrol (LGD 4033).
• Tablets are offered in 2 variants: 30mg S4 Andarine and 10mg Ligandrol, totaling 40mg per tablet for 27 tablets, or 1080mg in total, and 40mg per tablet for 54 tablets, totaling 2160mg.
• Capsules consist of 30mg S4 and 10mg Ligandrol, totaling 40mg per capsule and 2400mg in total.

Andarine S4

A scientific study published in 2005 examined the effects of Andarine S-4 in the skeletal muscles, bones, and pituitary glands of castrated male rats. A treatment protocol (3 and 10mg/kg S4- Andarine for 8 weeks) was commenced 12 weeks after castration. Andarine (doses 3 and 10 mg/kg) restored soleus muscle mass and strength and levator ani muscle mass to that seen prior to castration or in intact animals.

This makes S4 an investigational Selective androgen receptor modulator, for possible treatment of conditions related to muscle wasting, osteoporosis, and benign prostatic hyperplasia (BPH). It has the ability to mimic many of the beneficial pharmacologic effects associated with testosterone.

Ligandrol (LGD 4033)

Ligandrol is a novel nonsteroidal oral selective androgen receptor modulator currently being investigated in research as a potential treatment for conditions relating to muscle dystrophy and osteoporosis.

Recent studies investigated the effects of LGD 4033 on muscle tissue in ovariectomized rats. A daily dose of LGD was administered and calculated according to the body weight of each individual rat at the onset of the study. Results and changes were noted as soon as week 2, the control group having weighed significantly less than rats undergoing LGD treatment. This difference remained until the end of the study, irrespective of LGD treatments. Additionally, the LGD treatments resulted in a higher number of capillaries in all muscles studied. Longer randomized trials and research could potentially evaluate its efficacy in improving physical function and health outcomes in select populations.